<DOC>
	<DOC>NCT00535860</DOC>
	<brief_summary>The purpose of this study is to assess the clinical efficacy, safety, and tolerability of ViaDerm-shPTH [1-34] transdermal delivery in comparison to subcutaneous injection of rhPTH[1-34] following 3-month treatment in postmenopausal women with Osteoporosis</brief_summary>
	<brief_title>Efficacy &amp; Safety of ViaDerm-hPTH(1-34) Compared to Forteo SC in Postmenopausal Women With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Main Inclusive Criteria: Postmenopausal women aged between 55 to 85 years (inclusive) PosteriorAnterior lumbar vertebral and/or femoral neck BMD Tscore by DXA â‰¤2.5 SD. Have normal serum PTH, thyroid stimulating hormone (TSH) (only for patients treated with thyroid hormone), and prolactin values. Main Exclusive Criteria: Subjects who have a clinical significant or unstable medical or surgical condition that may preclude safe and complete study participation Current diagnoses of disorders known to affect bone metabolism including hyperthyroidism, hyperparathyroidism, osteomalacia, or Paget's disease Prior osteoporosis treatment with fluoride or strontium at any time; or any IV treatment with bisphosphonates in the past or oral bisphosphonate for more than 1 month in the past 24 months prior to randomization. Any condition or disease that may interfere with the ability to have, or to evaluate a DXA scan</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Transdermal</keyword>
	<keyword>hPTH(1-34)</keyword>
</DOC>